Drug intelligence / Profile preview

berberine + celecoxib

Development stage
Preclinical
Modality
Small Molecules
Administration
Oral
01

Overview

This is a combination of two small molecule drugs, berberine (盐酸小檗碱) and celecoxib (塞来昔布). Berberine is an isoquinoline alkaloid derived from plants such as Coptis chinensis, commonly used in China for its antimicrobial and anti-inflammatory properties, particularly in gastrointestinal disorders. Its mechanisms include inhibition of bacterial DNA synthesis and modulation of inflammatory pathways. Celecoxib is a selective cyclooxygenase-2 (COX-2) inhibitor classified as a nonsteroidal anti-inflammatory drug (NSAID), primarily used to treat pain and inflammation associated with arthritis and other conditions by blocking prostaglandin synthesis via COX-2 inhibition[7]. The rationale for combining these agents would be to leverage the complementary antimicrobial/anti-inflammatory effects of berberine with the potent anti-inflammatory action of celecoxib. There are no widely recognized brand or code names for this specific combination; it appears to be an investigational or off-label pairing rather than a marketed fixed-dose product.

Other names
盐酸小檗碱联合塞来昔布
02

Targets

DNA gyrasePTGS2 (Prostaglandin-Endoperoxide Synthase 2)

Beyond the preview

Go deeper on berberine + celecoxib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on berberine + celecoxib.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call